Rank #1723VYGR

Voyager Therapeutics, Inc.

$3.42

2.40% (Daily)

Market Cap

$190.15M

Revenue

$31.32M

Rank by MCap

#1723

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

Headquarters

Lexington, MA

Employees

172

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-...